v bryan lawlis founder president  ceo itero biopharmaceuticals timesjavascript is disabled market profiles login sign up login sign up   edit person v bryan lawlis founder president  ceo at itero biopharmaceuticals location san francisco bay area add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop v bryan lawlis founder president  ceo at itero biopharmaceuticals location san francisco bay area add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop dr lawlis is a founder and currently serves as the president and chief executive officer of itero biopharmaceuticals inc a privately held developer of valueadded followon and novel therapeutic proteins and antibodies that was founded in  dr lawlis served as president and chief executive officer of aradigm corporation from august  and served on its board of directors from february  continuing in both capacities until august  dr lawlis served as aradigm corporation’s president and chief operating officer from june  to august  and its chief operating officer from november  to june  previously dr lawlis cofounded covance biotechnology services a contract biopharmaceutical manufacturing operation served as its president and chief executive officer from  to  and served as chairman from  to  when it was sold to diosynth rtp inc a division of akzo nobel nv from  to  dr lawlis was employed at genencor inc and genentech inc his last position at genentech was vice president of process sciences dr lawlis currently holds board positions at itero biopharmaceuticals inc sutro biopharma inc and biomarin pharmaceutical inc dr lawlis holds a ba in microbiology from the university of texas at austin and a phd in biochemistry from washington state university  companies in career na related markets na colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags biotechnology biopharmaceuticals lifesciences topics of influence na na careers achievements investments related people edit view all v bryan lawliscareer  feb reform board member aug kalobios board member mar geron corporation board member jan coherus biosciences board member  biomarin pharmaceutical board member  sutro biopharma board member competencies edit view all v bryan lawliseducation   washington state university biochemistry university of texas at austin microbiology edit v bryan lawlisachievements and recognitions add milestone no milestones has been recorded for v bryan lawlis edit v bryan lawlislinks add link no links has been recorded for v bryan lawlis v bryan lawlisinvestmentsacquisitions no investments has been recorded for v bryan lawlis v bryan lawlisinvestments representing others no investment reps has been recorded for v bryan lawlis v bryan lawlisrelated people no colleagues and peers has been recorded for v bryan lawlis view all v bryan lawlisrecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees  companies absci appoints v bryan lawlis phd to board of directors absci appoints v bryan lawlis phd to board of directors news provided by absci may    et share this article portland ore may   prnewswire  absci announced today the appointment of v bryan lawlis phd to abscis board of directors dr lawlis has been the ceo and founder of numerous biotechnology companies and currently serves on the board of directors of biomarin pharmaceutical inc coherus biosciences inc and geron inc dr lawlis brings over  years of experience in the biotech industry where he has been a successful ceo entrepreneur scientist and pioneer in the fields of biopharmaceutical process development and manufacturing said sean mcclain founder and ceo of absci we are honored to welcome dr lawlis to our board of directors and we look forward to his input and guidance as we commercialize abscis solupro technology  i am very excited about the opportunity to join abscis board of directors said dr lawlis  abscis unique solupro technology has great potential to enhance speed and efficiency of development of key proteins in our industry  i look forward to sharing with the company my years of experience in the development of technologies for manufacturing of therapeutic proteins partnering solupro and commercialization of products manufactured by this approach previously dr lawlis cofounded and served as president and ceo of itero biopharmaceuticals inc from  to  prior to itero he was president and ceo of aradigm corporation from august  and served on its board of directors from february  continuing in both capacities until august  dr lawlis served as aradigm corporations president and coo from june  to august  dr lawlis cofounded covance biotechnology services a contract biopharmaceutical manufacturing operation and served as its president and ceo from  to  and chairman from  to  when it was acquired by diosynth inc a division of akzo nobel nv from  to  dr lawlis was employed at genencor inc and genentech inc his last position at genentech inc was vice president of process sciences dr lawlis is a board member of the following publicly traded companies biomarin  pharmaceutical inc coherus biosciences inc geron inc  in addition dr lawlis serves on the boards of two private companies sutro biopharma inc and reform biologics llc dr lawlis holds a ba in microbiology from the university of texas at austin and a phd in biochemistry from washington state university about absci absci is a global leader in protein production technologies the companys solupro™ expression platform achieves revolutionary yields of soluble and active protein products abscis unique approach accelerates drug discovery timelines increases manufacturing efficiencies and drastically reduces costs for the biopharmaceutical industry for more information please visit wwwabscibiocom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesabsciappointsvbryanlawlisphdtoboardofdirectorshtml source absci related links httpwwwabscibiocom may    et preview absci appoints daniel gold phd to board of directors apr    et preview absci secures  million in series a funding by phoenix venture partners my news release contains wide tables view fullscreen you just read absci appoints v bryan lawlis phd to board of directors news provided by absci may    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search lawlis v bryan  the wall street transcript v bryan lawlis v bryan lawlis jr is president and chief executive officer of aradigm corporation prior to his promotion in june  he held the position of president and chief operating officer and upon joining aradigm in  was the company’s chief operating officer previously dr lawlis was a founder of covance biotechnology services a contract biopharmaceutical manufacturing operation and served as its president and chief executive officer from  to  and as chairman from  to  when it was sold to diosynth rtp inc a division of akzo nobel from  to  dr lawlis was employed at genencor inc and genentech inc where his last position was vice president of process sciences dr lawlis hold a ba in microbiology from the university of texas at austin and a phd in biochemistry from washington state university related interviewsvbryan lawlis jr  aradigm corporation ardmoctober   cartlatest newsjames abate of centre asset management sees consumer demand driving new stock highsmalcolm e polley of stewart capital and how to play the health care stockstimothy biltz ceo of lumos networks identifies the key component for future g networksthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsdelivering longterm results with a riskmanaged growth fundjames a abate published july   in investing strategiescompanies covered amat jnj coh rl cog nvda adbe atvi klac amzn nflx goog fb glw mu   wfm jwn cmg gps eqt rice spls buy finding investments with favorable risk and reward opportunitieshenry beukema published july   in investing strategiescompanies covered orcl msft nsrgy amzn wfm lrlcy agn lnr buy better returns and lower risk in the midcap spacemalcolm e polley published july   in investing strategiescompanies covered praa hurn fii fl nke amzn wfm wba rad buy most popular reportswireless communications  telecom published july  buy investing strategies published july  buy investing strategies published june  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsdelivering longterm results with a riskmanaged growth fundfinding investments with favorable risk and reward opportunitiesbetter returns and lower risk in the midcap space analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google v bryan lawlis of biomarin pharmaceutical inc board of directors   welcome company news company site premium log in membership home portfolio stocks bonds funds etfs cef markets tools real life finance discuss investing ideas fund analyst picks picks by category fund pick performance picks  pans enewsletter fund spy column fund spy book bond squad fund video reports fundinvestor newsletter etf investing fund family experts fund reports all fund analyst reports fund stewardship reports fund ratings highestrated value highestrated growth highestrated largecap highestrated midcap highestrated smallcap foreign fund standouts star rating performance rating methodology fund performance top month performers top ytd performers top year performers top year performers top year performers fund category returns biggest daily nav changes closedend funds exchangetraded funds quarterly market outlook fund screeners basic screeners fund screener longterm winners solid smallgrowth funds conservative bond funds premium screeners premium fund screener index funds hidden gems lowerrisk foreign funds video center biomarin pharmaceutical inc  bmrn add to portfolioget email alertsprint this pagepdf reportdata questionquotechartstock analysisperformancekey ratiosfinancialsvaluationinsidersownershipfilingsbondsoverviewexecutive compensationinsider activitykey executivesboard of directorscommittees board of directors  v bryan lawlis v bryan lawlis independent director profile connections biography v bryan lawlis phd joined our board in june  since august  he has served as the president and chief executive officer of itero biopharmaceuticals llc a privately held company that holds the assets of itero biopharmaceuticals inc dr lawlis cofounded and served as president and chief executive officer of itero biopharmaceuticals inc from  until it discontinued operations in august  dr lawlis served as president and chief executive officer of aradigm corporation a pharmaceutical company aradigm from august  to august  and served on its board of directors from february  to august  continuing in both capacities until august  dr lawlis previously served as aradigms president and chief operating officer from june  to august  and its chief operating officer from november  to june  prior to his time at aradigm dr lawlis cofounded covance biotechnology services a contract biopharmaceutical manufacturing operation served as its president and chief executive officer from  to  and served as chairman from  to  when it was sold to diosynth rtp inc a division of akzo nobel nv from  to  dr lawlis was employed at genencor inc a biotechnology company and genentech inc his last position at genentech inc was vice president of process sciences dr lawlis has served on the board of geron corporation a public biopharmaceutical company since march  and has served as a member of the board of directors of coherus biosciences inc a public biotechnology company coherus since october  he previously served on the board of kalobios pharmaceuticals inc a public biopharmaceutical company from august  until september  and acted as the chairman of the scientific advisory board for coherus from november  to june  dr lawlis holds board position at four privately held companies absci llc itero biopharmaceuticals llc reform biologics llc and sutro biopharma inc since october  dr lawlis has served as an advisor to phoenix venture partners a venture capital firm focusing on manufacturing technologies dr lawlis holds a ba in microbiology from the university of texas at austin and a phd in biochemistry from washington state university board membership company name board member since board committees biomarin pharmaceutical inc  auditboardcompensationcorporate governance and nominatingscience and technology geron corp  auditboardcompensation v bryan lawlis is connected to  board memberssee list of all board connections   we value your feedback let us know what you think site directory site map our products corrections help advertising opportunities licensing opportunities glossary rss mobile portfolio affiliate careers international sites australia canada china france germany hong kong italy the netherlands norway spain uk switzerland stocks by name  ticker  star rating  market cap  stock type  sector  industry mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name etfs by star rating  category  total assets  symbol  ticker  name articles by title  date  author  collection  interest  popularity investment categories by topic  sector  key indicators  user interest  market cap  industry premium stocks by name  ticker  star rating  market cap  stock type  sector  industry premium mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name premium etfs by star rating  category  total assets  symbol  ticker  name popular articles by title  date  author  collection  interest  popularity popular investment categories by topic  sector  key indicators  user interest  market cap  industry independent insightful trusted morningstar provides stock market analysis equity mutual fund and etf research ratings and picks portfolio tools and option hedge fund ira k and  plan research our reliable data and analysis can help both experienced enthusiasts and newcomers  copyright morningstar inc all rights reserved please read our terms of useand privacy policydow jones industrial average sp  nasdaq and morningstar index market barometer quotes are realtime russell  quote is  minutes delayed v bryan lawlis jr phd  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in v bryan lawlis jr phd board member at biomarin pharmaceutical inc view full profile are you v bryan lawlis jr phd claim your profile   sign up for equilar atlas and view v bryan lawlis jr phds full profile with equilar atlas you can identify corporate executives in v bryan lawlis jr phds network and community follow changes in v bryan lawlis jr phds employment and moneyinmotion connect with v bryan lawlis jr phd through your network of contacts v bryan lawlis jr phds executive work history current board member biomarin pharmaceutical inc board member geron corporation past to view v bryan lawlis jr phds complete executive work history sign up now education ba university of texas at austin phd washington state university age      v bryan lawlis jr phds biography the board has nominated dr lawlis for his extensive experience in manufacturing biotechnology and other pharmaceutical products research and development of drug products and managing and conducting clinical trials and drug regulatory processes v bryan lawlis phd joined our board in june  since august  he has served as the president and chief executive officer of itero biopharmaceuticals llc a privately held company that holds the assets of itero biopharmaceuticals inc dr lawlis cofounded and served as president and chief executive officer of itero biopharmaceuticals inc from  until it discontinued operations in  read more the board has nominated dr lawlis for his extensive experience in manufacturing biotechnology and other pharmaceutical products research and development of drug products and managing and conducting clinical trials and drug regulatory processes v bryan lawlis phd joined our board in june  since august  he has served as the president and chief executive officer of itero biopharmaceuticals llc a privately held company that holds the assets of itero biopharmaceuticals inc dr lawlis cofounded and served as president and chief executive officer of itero biopharmaceuticals inc from  until it discontinued operations in august  dr lawlis served as president and chief executive officer of aradigm corporation a pharmaceutical company aradigm from august  to august  and served on its board of directors from february  to august  continuing in both capacities until august  dr lawlis previously served as aradigms president and chief operating officer from june  to august  and its chief operating officer from november  to june  prior to his time at aradigm dr lawlis cofounded covance biotechnology services a contract biopharmaceutical manufacturing operation served as its president and chief executive officer from  to  and served as chairman from  to  when it was sold to diosynth rtp inc a division of akzo nobel nv from  to  dr lawlis was employed at genencor inc a biotechnology company and genentech inc his last position at genentech inc was vice president of process sciences dr lawlis has served on the board of geron corporation a public biopharmaceutical company since march  and has served as a member of the board of directors of coherus biosciences inc a public biotechnology company coherus since october  he previously served on the board of kalobios pharmaceuticals inc a public biopharmaceutical company from august  until september  and acted as the chairman of the scientific advisory board for coherus from november  to june  dr lawlis holds board position at four privately held companies absci llc itero biopharmaceuticals llc reform biologics llc and sutro biopharma inc since october  dr lawlis has served as an advisor to phoenix venture partners a venture capital firm focusing on manufacturing technologies dr lawlis holds a ba in microbiology from the university of texas at austin and a phd in biochemistry from washington state university source biomarin pharmaceutical inc on    sign up for equilar atlas and view v bryan lawlis jr phds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like v bryan lawlis jr phd more specifically youll be able to identify corporate executives in v bryan lawlis jr phds network and community follow changes in v bryan lawlis jr phds employment and moneyinmotion connect with v bryan lawlis jr phd through your network of conections view full profile   search for over  executive profiles bio example v bryan lawlis jr phd v bryan lawlis jr phds connections  sign up now to view v bryan lawlis jr phds  connections » henry j fuchs president worldwide research and development biomarin pharmaceutical inc daniel m bradbury board member illumina inc james i healy former board member ascendis pharma as david e pyott lead independent director avery dennison pierre lapalme board member insys therapeutics inc peter k watler chief technical officer coherus biosciences inc david j earp former senior vice president corporate transactions geron corporation jeanfrederic viret chief financial officer coherus biosciences inc gary a lyons chairman of the board rigel pharmaceuticals inc william d young chairman nanostring technologies inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla david j oconnor president and ceo the madison square garden company claiborne p deming chairman of the board murphy oil corporation × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   v bryan lawlis ph d promoted to ceo of  employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       v bryan lawlis phd promoted to ceo of aradigm ardm tweet   pm hayward calif july  prnewswirefirstcall  aradigm corporation today announced that it has promoted v bryan lawlis phd to the position of president and chief executive officer from his previous post of president and chief operating officer effective august   aradigms chairman and current ceo richard thompson will remain as chairman of the board of directors dr lawlis has more than  years of senior management experience in the biotechnology and pharmaceutical industries and since joining aradigm in  has been responsible for leading the daytoday operations of the company photo httpwwwnewscomcomcgibinprnhsfth  richard thompson stated this promotion is part of a planned succession and acknowledges the significant contributions that bryan has made throughout his career and during his time at aradigm i am confident in bryans ability to lead the company and i look forward to working closely with him in his new role i will continue to be active in the company focusing on commercial and financial strategies as we move towards our first product launch dr lawlis commented on his nearterm objectives as ceo we will accelerate aradigms path to market using the intraject technology which is being validated in clinical trials this summer intraject delivery is appropriate for both small molecules and proteins and offers an accelerated clinical and regulatory route for products already dosed by subcutaneous injection aradigm will move forward aggressively to realize this potential through its own product development efforts and with partners at the same time we will continue to work with novo nordisk on our phase  development program for the pulmonary delivery of insulin using our aerx platform and with our other partners for the aerx technology who are pursuing earlierstage pulmonary drug delivery programs dr lawlis began at aradigm in  as chief operating officer and was promoted to president and chief operating officer in june  prior to joining aradigm dr lawlis was a founder of covance biotechnology services a contract biopharmaceutical manufacturing operation where he served as its president and chief executive officer from  to  and its chairman from  to  from  to  dr lawlis was employed at genencor inc and genentech inc where his last position was vice president of process sciences dr lawlis holds a ba in microbiology from the university of texas at austin and a phd in biochemistry from washington state university under his operational leadership aradigm has enhanced its core manufacturing competencies completed critical commercial scaleup efforts successfully acquired and advanced the development of intraject and strengthened the operations management team aradigm is working to improve the quality of life for patients through the development of new therapies delivered via its innovative liquid delivery technologies the companys aerxr advanced pulmonary delivery system and its intrajectr needlefree delivery system provide leading pharmaceutical and biotechnology partners with effective solutions for product selfadministration the companys most advanced product is in phase  clinical trials for the treatment of diabetes in partnership with novo nordisk a world leader in diabetes care more information about aradigm can be found at httpwwwaradigmcom except for the historical information contained herein this news release contains forwardlooking statements that involve risk and uncertainties including clinical results the timely availability and acceptance of new products the impact of competitive products and pricing and the management of growth as well as the other risks detailed from time to time in aradigm corporations securities and exchange commission sec filings including the companys annual report on form k and quarterly reports on form q note aerx and intraject are registered trademarks of aradigm contact chris keenan or joe dorame aradigm rcg capital markets group inc   photo newscom httpwwwnewscomcomcgibinprnhsfthap photoexpress network prnprn photo desk photodeskprnewswirecomaradigm corporation contact chris keenan of aradigm corporation  or joedorame of rcg capital markets group inc  for aradigmcorporation web site httpwwwaradigmcom read at biospacecom related news aradigm ardm and novo nordisk nvo release interim analysis of initial pulmonary insulin phase  trial all primary safety endpoints met postmeal glucose levels require additional analysiscerus corporation cers increases development focus on therapeutic vaccines strategic realignment reduces expensesaradigm ardm reports first quarter  financial resultsknud aunstrup joins nuevolution as chief executive officeraradigm ardm to host first quarter  financial conference callcompugen cgen establishes small molecule drug discovery subsidiaryaradigm ardm to host first quarter  financial conference callroche to strengthen global leadership in biotechnology manufacturing  new jobsaradigm ardm selects final intraject configurationbiopure corporation bpur appoints new president and chief executive officer and restructures the company cuts jobs please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • aradigm corporation   • biotechpharma  personnel                 homeabout ustechnologynewsroomcareerscontact us absci appoints v bryan lawlis phd to board of directors portland ore may   prnewswire  absci announced today the appointment of v bryan lawlis phd to abscis board of directors dr lawlis has been the ceo and founder of numerous biotechnology companies and currently serves on the board of directors of biomarin pharmaceutical inc coherus biosciences inc and geron inc dr lawlis brings over  years of experience in the biotech industry where he has been a successful ceo entrepreneur scientist and pioneer in the fields of biopharmaceutical process development and manufacturing said sean mcclain founder and ceo of absci we are honored to welcome dr lawlis to our board of directors and we look forward to his input and guidance as we commercialize abscis solupro technology  i am very excited about the opportunity to join abscis board of directors said dr lawlis  abscis unique solupro technology has great potential to enhance speed and efficiency of development of key proteins in our industry  i look forward to sharing with the company my years of experience in the development of technologies for manufacturing of therapeutic proteins partnering solupro and commercialization of products manufactured by this approach previously dr lawlis cofounded and served as president and ceo of itero biopharmaceuticals inc from  to  prior to itero he was president and ceo of aradigm corporation from august  and served on its board of directors from february  continuing in both capacities until august  dr lawlis served as aradigm corporations president and coo from june  to august  dr lawlis cofounded covance biotechnology services a contract biopharmaceutical manufacturing operation and served as its president and ceo from  to  and chairman from  to  when it was acquired by diosynth inc a division of akzo nobel nv from  to  dr lawlis was employed at genencor inc and genentech inc his last position at genentech inc was vice president of process sciences dr lawlis is a board member of the following publicly traded companies biomarin  pharmaceutical inc coherus biosciences inc geron inc  in addition dr lawlis serves on the boards of two private companies sutro biopharma inc and reform biologics llc dr lawlis holds a ba in microbiology from the university of texas at austin and a phd in biochemistry from washington state university about absciabsci is a global leader in protein production technologies the companys solupro™expression platform achieves revolutionary yields of soluble and active protein products abscis unique approach accelerates drug discovery timelines increases manufacturing efficiencies and drastically reduces costs for the biopharmaceutical industry for more information please visitwwwabscibiocom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesabsciappointsvbryanlawlisphdtoboardofdirectorshtml homeabout ustechnologynewsroomcareerscontact us  absci llc  all rights reserverd site by skyhound internet v bryan lawlis jr phd executive profile  biography  bloomberg july    pm et biotechnology company overview of coherus biosciences inc snapshotpeople  overviewboard memberscommittees executive profile v bryan lawlis jr phdscience director and director coherus biosciences incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background dr v bryan lawlis jr phd serves as science director at coherus biosciences inc dr lawlis has been an advisor of phoenix venture partners since october  dr lawlis cofounded itero biopharmaceuticals inc in  and served as its chief executive officer and president from  to  dr lawlis is the chief executive officer and founder of numerous biotechnology companies he has over years of biotech industry experience prior to joining itero  in  he served as the chief executive officer of aradigm corporation from august   to august  and its president from june   to august  he served as the chief operating officer of aradigm corporation from november  to august  he served as the chief executive officer and president of fujifilm diosynth biotechnologies inc dr lawlis served as the acting chairman president and chief executive officer of diosynth rtp inc he founded covance biotechnology services and served as its president and chief executive officer from  to  and its executive chairman from  to  from  to  he was employed at genencor inc and genentech inc he served as vice president of process sciences at genentech inc dr lawlis served as a director of itero biopharmaceuticals inc he has been a director of absci llc since may   he has been an independent director of biomarin pharmaceutical inc since june  and geron corporation since march   he serves as a director of sutro biopharma inc and reform biologics llc he serves as a member of advisory board of phoenix venture partners he served as the chairman of scientific advisory board at coherus biosciences inc since november  until june  and served as its member of scientific advisory board since november  and director since may  he served as director of glycofi inc and aradigm corp from february   to august  he served as a director of kalobios pharmaceuticals inc from august  to october   dr lawlis holds a phd in biochemistry from washington state university he has a ba in microbiology from the university of texas at austinread full background corporate headquarters  twin dolphin driveredwood city california united statesphone fax  board members memberships directorsutro biopharma incpresentindependent directorbiomarin pharmaceutical incpresentindependent directorgeron corporationpresentscience director and directorcoherus biosciences incpresentdirectorabsci llc education ba the university of texas austinphd washington state universitypullman other affiliations aradigm corporationbiomarin pharmaceutical incgenentech incgeron corporationfujifilm diosynth biotechnologies incglycofi incthe university of texas austinwashington state universitypullmankalobios pharmaceuticals incsutro biopharma incitero biopharmaceuticals incphoenix venture partners llcabsci llc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation total annual cash compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact coherus biosciences inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close coherus biosciences appoints dr v bryan lawlis jr to board of directors coherus biosciences appoints dr v bryan lawlis jr to board of directors jul    et from coherus biosciences english deutschland  deutsch español france  français latin america  español brazil  português coherus biosciences logo prnewsfotocoherus biosciences     facebook twitter pinterest coherus biosciences logo prnewsfotocoherus biosciences redwood city calif july   prnewswire  coherus biosciences inc coherus announced today the appointment of v bryan lawlis jr phd former president and ceo of itero biopharmaceuticals to its board of directors it is a privilege to join this talented board of directors and i am excited about the opportunity to work with the board and management to make coherus the leader in the emerging business of biosimilars dr lawlis stated i look forward to working with denny and his veteran team of biopharmaceutical industry experts as we strive to bring the highest quality biosimilars to patients worldwide bryan is a seasoned executive who brings over  years of scientific and technical leadership in the biopharmaceutical process sciences to coherus said denny lanfear president and ceo of coherus as chairman of our scientific advisory board bryan made significant contributions to the advancement of our products with the support of the other distinguished scientists on our sab  bryan brings an essential skillset and experience base to our board of directors as we prepare for commercialization of our biosimilar therapeutics and scale up operations dr lawlis cofounded and served as president and ceo of itero biopharmaceuticals inc from  until it discontinued operations in august  prior to itero he was president and ceo of aradigm corporation from august  and served on its board of directors from february  continuing in both capacities until august   dr lawlis served as aradigm corporations president and coo from june  to august  dr lawlis cofounded covance biotechnology services a contract biopharmaceutical manufacturing operation and served as its president and ceo from  to  and chairman from  to  when it was sold to diosynth inc a division of akzo nobel nv  from  to  dr lawlis was employed at genencor inc and genentech inc  his last position at genentech inc was vice president of process sciences dr lawlis holds board memberships on the publicly traded companies of biomarin pharmaceutical inc geron inc and kalobios inc  in addition dr lawlis serves on the boards of two private companies sutro biopharma inc and reform llc dr lawlis holds a ba in microbiology from the university of texas at austin and a phd in biochemistry from washington state university about coherus biosciences inc coherus is a leading biologics platform company focused on delivering highquality biosimilar therapeutics that will expand patient access to lifechanging medications worldwide headquartered in the san francisco bay area and founded by a group of biotech pioneers who helped build americas first generation biotherapeutics industry coherus has developed a collaborative business model that leverages a strategic consortium of service providers aligned through ownership and shared incentives coherus global commercialization partnerships include toptier biopharma companies in europe asia and latin america biosimilars are intended for use in place of existing branded biologics to treat a range of chronic and often lifethreatening diseases with the potential to reduce costs and expand patient access for additional information please visit wwwcoheruscom contact – beth jimison – bjimisoncoheruscom   logo  httpphotosprnewswirecomprnhsflogo source coherus biosciences related links httpwwwcoheruscom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jul    et preview coherus biosciences nombra al doctor v bryan lawlis jr como miembro del consejo de dirección jan    et preview coherus biosciences es invitada a hacer presentación en la conferencia anual de cuidado de salud  de jp morgan my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search